A prospective, interventional case series involved 20 eyes of 20 patients with refractory subretinal fluid and vPED treated with at least three injections of intravitreal anti-VEGF prior to study inclusion. The gene discussed is VEGFA; the disease is vitreoretinopathy with phalangeal epiphyseal dysplasia.